A Targetable EGFR-Dependent Tumor-Initiating Program in Breast CancerPaul Savage, Jiannis Ragoussis, Alexis Blanchet-Cohen et al.|Cell Reports|2017Cited by 78
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerGiulia Viale, Victoria de Giorgio‐Miller, Gavin C. Higgins et al.|ESMO Open|2023Cited by 76
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancerStephanie Totten, Josie Ursini‐Siegel, Young Kyuen Im et al.|Nature Communications|2021Cited by 61
SPEN, a new player in primary cilia formation and cell migration in breast cancerStéphanie Légaré, Mark Basik|Breast Cancer Research|2017Cited by 57
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumorsPaul Savage, Morag Park, Alain Pacis et al.|Communications Biology|2020Cited by 56